Proleukin® Observational Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
The purpose of this registry is to collect information on patients who are receiving treatment with Proleukin in an organized way, and to learn more about patient care during and after treatment.
• Must have received at least one course of high dose IL-2 or Proleukin
Multiple Tumor Types
Brendan Curti, M.D.
Prometheus Laboratories, Inc
- Oncology and Hematology Care Eastside
- Providence Portland Medical Center